GlassScriptPhysician profile
Emily King Johnson
NPI 1407954282
$3,295.67
in general payments reported to CMS, 2019-2025
33 companies · $576 in 2025
The $576 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $322 · 2022: $571 · 2023: $783 · 2024: $1,043 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,402.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $804.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $534.76 | 2021-2025 | |
| Abbvie INC. | $352.84 | 2021-2025 | |
| Lilly USA, LLC | $217.71 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $161.25 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $137.99 | 2023-2025 | Cologuard Collection Kit |
| Becton, Dickinson and Company | $120.98 | 2024 | Arista Ah Flexitip |
| Amgen INC. | $103.66 | 2021-2024 | Repatha, Otezla |
| Davol INC. | $94.84 | 2024-2025 | Arista, Arista Ah Flexitip |
| Merck Sharp & Dohme LLC | $71.22 | 2022-2023 | Belsomra |
| Astrazeneca Pharmaceuticals LP | $68.28 | 2022-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.97 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $54.94 | 2023-2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $54.19 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $53.42 | 2023 | Gemtesa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $37.54 | 2021-2022 | |
| Inspire Medical Systems, INC. | $32.51 | 2023-2025 | Inspire |
| Cardiva Medical, INC. | $31.82 | 2023 | Cardiva Vascade 6/7f Vcs |
| Bayer Healthcare Pharmaceuticals INC. | $31.40 | 2022-2025 | |
| Organogenesis INC. | $29.39 | 2023 | Puraply |
| Acadia Pharmaceuticals INC | $26.74 | 2025 | Nuplazid |
| Sanofi-Aventis U.S. LLC | $25.97 | 2024 | |
| Shield Therapeutics INC | $24.61 | 2022 | |
| Mylan Specialty L.P. | $21.46 | 2023 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.34 | 2025 | Xifaxan |
| Ultragenyx Pharmaceutical INC. | $18.72 | 2023 | |
| Janssen Pharmaceuticals, INC | $18.71 | 2024 | Xarelto |
| Tris Pharma INC | $17.31 | 2024 | Dyanavel Xr |
| W. L. Gore & Associates, INC. | $15.05 | 2021 | |
| Esperion Therapeutics, INC. | $14.34 | 2021 | |
| Astellas Pharma US INC | $13.54 | 2023 | Veozah |
| Kowa Pharmaceuticals America, INC. | $12.12 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.